Department of Cardiology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, PR China.
School of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, PR China.
Gene. 2025 Jan 15;933:148920. doi: 10.1016/j.gene.2024.148920. Epub 2024 Sep 4.
Chronic heart failure (CHF) combined with hyperuricemia (HUA) is a comorbidity that is hard to diagnose by a single biomarker. Exosomal miRNAs are differentially expressed in cardiovascular diseases and are closely associated with regulating most biological functions. This study aimed to provide evidence for miRNA as a new molecular marker for precise diagnosis of the comorbidity of CHF with HUA and further analyze the potential targets of differentially expressed miRNA. This controlled study included 30 CHF patients combined with HUA (Group T) and 30 healthy volunteers (Group C). 6 peripheral blood samples from Group T and Group C were analyzed for exosomal miRNAs by high-throughput sequencing and then validated in the remaining 24 peripheral blood samples from Group T and Group C by applying real-time PCR (RT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using R software to predict the differential miRNAs' action targets. 42 differentially expressed miRNAs were detected (18 upregulated and 24 downregulated), in which miR-27a-5p was significantly upregulated (P<0.01), and miR-139-3p was significantly downregulated (P<0.01) in Group T. The combination of miR-27a-5p and miR-139-3p predicted the development of CHF combined with HUA with a maximum area under the curve (AUC) of 0.899 (95 % CI: 0.812-0.987, SEN=79.2 %, SPE=91.7 %, J value = 0.709). GO and KEGG enrichment analysis revealed that the differentially expressed miRNAs had a role in activating the AMPK-mTOR signaling pathway to activate the autophagic response. Collectively, our findings suggest that upregulated exosomal miR-27a-5p combined with downregulated exosomal miR-139-3p can be used as a novel molecular marker for precise diagnosis of CHF combined with HUA and enhanced autophagy by AMPK-mTOR signaling pathway may be one pathogenesis of the differentially expressed miRNAs.
慢性心力衰竭(CHF)合并高尿酸血症(HUA)是一种难以通过单一生物标志物诊断的合并症。外泌体 miRNA 在心血管疾病中表达差异,并与调节大多数生物学功能密切相关。本研究旨在为 miRNA 作为 CHF 合并 HUA 精确诊断的新分子标志物提供证据,并进一步分析差异表达 miRNA 的潜在靶点。这项对照研究纳入了 30 例 CHF 合并 HUA 患者(T 组)和 30 名健康志愿者(C 组)。通过高通量测序分析 T 组和 C 组的 6 份外周血样本中的外泌体 miRNA,然后通过应用实时 PCR(RT-PCR)分析 T 组和 C 组的其余 24 份外周血样本中的差异表达 miRNA。使用 R 软件对差异表达 miRNA 的作用靶点进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析。检测到 42 个差异表达 miRNA(18 个上调和 24 个下调),其中 miR-27a-5p 在 T 组中显著上调(P<0.01),miR-139-3p 显著下调(P<0.01)。miR-27a-5p 和 miR-139-3p 的组合预测 CHF 合并 HUA 的发展,曲线下面积(AUC)最大为 0.899(95%CI:0.812-0.987,SEN=79.2%,SPE=91.7%,J 值=0.709)。GO 和 KEGG 富集分析显示,差异表达的 miRNA 在外泌体中具有激活 AMPK-mTOR 信号通路以激活自噬反应的作用。综上所述,我们的研究结果表明,上调的外泌体 miR-27a-5p 与下调的外泌体 miR-139-3p 联合使用可以作为 CHF 合并 HUA 精确诊断的新型分子标志物,AMPK-mTOR 信号通路增强自噬可能是差异表达 miRNA 的一种发病机制。